[July 29, 2016] |
|
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502):
|
Strong first quarter results and confidence in Management Guidance
|
•
|
|
Underlying revenue grew +9.1%, driven by a +15.3% increase of
Takeda's Growth Drivers (GI, Oncology, CNS and Emerging Markets).
(Reported revenue declined -2.8% to 434.0 billion yen, due to
divestments and currency impacts)
|
•
|
|
Underlying Core Earnings advanced +40.4% (reported operating
profit was 152.9 billion yen, up from 49.6 billion yen in Q1, 2015)
|
•
|
|
Underlying Core Net Profit and EPS were up +54.2% (reported EPS
increased to 127 yen, from 31 yen in Q1, 2015)
|
|
|
|
Takeda's Growth Drivers are accelerating
|
•
|
|
GI underlying revenue advanced +35.3%, driven by ENTYVIO(®) and
TAKECAB(®)
|
•
|
|
Oncology underlying revenue grew +6.6% (+7.5% excluding VELCADE(®)
royalties), driven by NINLARO(® )and ADCETRIS(®)
|
•
|
|
CNS underlying revenue of +31.5% was boosted by strong
TRINTELLIX(®) performance
|
•
|
|
Emerging Markets underlying revenue growth was +3.9%
|
|
|
|
All regions are growing, driven by innovative products
|
•
|
|
Japan underlying revenue was up +9.7%, driven by TAKECAB(®),
AZILVA(®) and LOTRIGA(®)
|
•
|
|
US underlying revenue growth of +14.9%, led by ENTYVIO(®),
NINLARO(® )and TRINTELLIX(®)
|
•
|
|
Europe and Canada underlying revenue grew +6.2%, reflecting
ENTYVIO(®) and ADCETRIS(®)
|
•
|
|
Emerging Markets underlying revenue was up +3.9%, reflecting
growth in China (+12.6%), Russia (+9.5%) and Brazil (+1.0%)
|
|
Full-year forecast (reported base) has been maintained. R&D
transformation does not affect our FY2016 guidance or dividend
payment (see separate press release for more details)
|
|
|
|
Christophe Weber, President and Chief Executive Officer of Takeda,
commented: "Takeda had a strong start to FY2016, as we focus
on executing our strategic roadmap. It is promising that our growth
driver products are contributing strongly to each region's underlying
revenue growth, especially ENTYVIO®, NINLARO®,
ADCETRIS®, TRINTELLIX®,
and TAKECAB®. Takeda will refocus research &
development on targeted therapeutic areas - Oncology, Gastroenterology
(GI) and Central Nervous System (CNS), plus Vaccines, and concentrate
its R&D activities in Japan and the U.S. to build a world-leading R&D
organization and pipeline. I am confident that these achievements and
initiatives will result in Takeda's sustainable future growth as a
leading, global innovative pharmaceutical company."
|
Reported Results for
|
1Q (April - June) of FY2016
|
Reported base
|
|
FY 2015
|
|
FY 2016
|
|
Growth
|
(billion yen)
|
|
Q1
|
|
Q1
|
|
|
|
Underlying2
|
Revenue
|
|
446.3
|
|
434.0
|
|
-2.8%
|
|
+9.1%
|
Core Earnings1
|
|
83.7
|
|
77.1
|
|
-7.9%
|
|
+40.4%
|
Operating Profit
|
|
49.6
|
|
152.9
|
|
+208.6%
|
|
N/A
|
Net Profit3
|
|
24.6
|
|
99.5
|
|
+304.9%
|
|
N/A
|
EPS
|
|
31 yen
|
|
127 yen
|
|
+306.5%
|
|
N/A
|
Core EPS
|
|
65 yen
|
|
71 yen
|
|
+8.7%
|
|
+54.2%
|
1
|
|
Core Earnings is calculated by taking reported gross profit and
deducting SG&A expenses and R&D expenses.
|
|
|
In addition, certain other items that are significant in value and
non-recurring or non-core in nature may also be adjusted.
|
2
|
|
"Underlying growth", comparing two periods of financial results
under a common basis, shows the real performance of the business.
Takeda adopts "Underlying Growth" of revenue, Core Earnings and Core
EPS as its indicators for management guidance. It excludes the
impact of foreign exchange and divestments.
|
3
|
|
Attributable to the owners of the company
|
|
Takeda maintains full-year Management Guidance and reported base
forecast for FY2016:
FY2016
|
Management Guidance
|
|
|
|
Underlying Revenue
|
|
Mid-single digit growth (%)
|
|
Underlying Core Earnings
|
|
Low- to mid-teen growth (%)
|
|
Underlying Core EPS
|
|
Low- to mid-teen growth (%)
|
|
Annual Dividend per Share
|
|
180 yen
|
|
Reported
|
Base Forecast for FY2016
|
|
|
|
(billion yen1)
|
|
Revenue
|
|
|
|
|
|
1,720.0
|
|
|
|
|
|
R&D Expenses
|
|
|
|
|
|
325.0
|
|
|
|
|
|
Operating Profit
|
|
|
|
|
|
135.0
|
|
|
|
|
|
Net Profit 2
|
|
|
|
|
|
88.0
|
|
|
|
|
|
EPS
|
|
|
|
|
|
112 yen
|
|
|
|
|
1 The exchange rate assumptions for FY2016: 1 US$=110 yen, 1
euro=125 yen 2 Attributable to the owners of the company
For more details on Takeda's FY2016 Q1 results and other financial
information please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited Takeda
Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as our presence in Emerging
Markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728006765/en/
[ Back To TMCnet.com's Homepage ]
|